Pharmacogenomics and Tumor Biomarkers

The main interest of the Pharmacogenomics and Tumor Biomarkers Group is understanding how genomic variation modifies drug treatment response, with the ultimate goal of using this knowledge to design more specific drug treatments. In cancer, drug therapy failure is a major clinical problem and developing safer and more effective anticancer drug treatment strategies is urgently needed. Our top priority is improving the survival and quality of life of cancer patients. To this end, we focus on the discovery of new mechanisms of drug sensitivity/ resistance, the identification of biomarkers predictive of treatment response, and proposing novel cancer therapeutic vulnerabilities. The identification of germline genetic variants that increase the risk of drug toxicity is also a fundamental part of our objectives. To achieve these goals, we perform translational research that integrates genomics and bioinformatics with the clinical expertise of oncology departments.